BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries

EBioMedicine

Volumn 2, Issue 11, 2015, Pages 1650-1661

  Wang, Bowen ^a   Zhang, Mengxue ^a   Takayama, Toshio ^a   Shi, Xudong ^a   Roenneburg, Drew Alan ^a   Craig Kent, K ^a   Guo, Lian Wang ^a  

^a University of Wisconsin Health   (United States)

Author keywords

BET; BRD4; Epigenetic reader; Intimal hyperplasia; Smooth muscle cell

Indexed keywords

BRD2 PROTEIN; BRD3 PROTEIN; BRD4 PROTEIN; BROMODOMAIN INHIBITOR; CASPASE 3; CASPASE 7; CYCLINE; INTERLEUKIN 1BETA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AUTACOID; AZEPINE DERIVATIVE; CYTOKINE; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BRDU ASSAY; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; NEOINTIMA; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CAROTID ARTERY; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENETICS; HYPERPLASIA; INTIMA; METABOLISM; PATHOLOGY; PROTEIN DOMAIN; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE; VEIN;

ANIMALS; AZEPINES; CAROTID ARTERIES; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NUCLEAR PROTEINS; PROTEIN INTERACTION DOMAINS AND MOTIFS; RATS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TRANSCRIPTION FACTORS; TRIAZOLES; TUNICA INTIMA; VEINS;

EID: 84958928057     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.09.045     Document Type: Article

References (39)

1. Abrahimi P., Chang W.G., Kluger M.S., Qyang Y., Tellides G., Saltzman W.M., Pober J.S. Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9. Circ. Res. 2015, 117:121-128.
2. Alexander M.R., Owens G.K. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu. Rev. Physiol. 2012, 74:13-40.
3. Amaral P.P., Bannister A.J. Re-place your BETs: the dynamics of super enhancers. Mol. Cell 2014, 56:187-189.
4. Anand P., Brown J.D., Lin C.Y., Qi J., Zhang R., Artero P.C., Alaiti M.A., Bullard J., Alazem K., Margulies K.B., Cappola T.P., Lemieux M., Plutzky J., Bradner J.E., Haldar S.M. BET bromodomains mediate transcriptional pause release in heart failure. Cell 2013, 154:569-582.
5. Asangani I.A., Dommeti V.L., Wang X., Malik R., Cieslik M., Yang R., Escara-Wilke J., Wilder-Romans K., Dhanireddy S., Engelke C., Iyer M.K., Jing X., Wu Y.M., Cao X., Qin Z.S., Wang S., Feng F.Y., Chinnaiyan A.M. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014, 510:278-282.
6. Baratta M.G., Schinzel A.C., Zwang Y., Bandopadhayay P., Bowman-Colin C., Kutt J., Curtis J., Piao H., Wong L.C., Kung A.L., Beroukhim R., Bradner J.E., Drapkin R., Hahn W.C., Liu J.F., Livingston D.M. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:232-237.
7. Baud M.G., Lin-Shiao E., Cardote T., Tallant C., Pschibul A., Chan K.H., Zengerle M., Garcia J.R., Kwan T.T., Ferguson F.M., Ciulli A. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science 2014, 346:638-641.
8. Brown J.D., Lin C.Y., Duan Q., Griffin G., Federation A.J., Paranal R.M., Bair S., Newton G., Lichtman A.H., Kung A.L., Yang T., Wang H., Luscinskas F.W., Croce K.J., Bradner J.E., Plutzky J. NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol. Cell 2014, 56:219-231.
9. Davies M.G., Owens E.L., Mason D.P., Lea H., Tran P.K., Vergel S., Hawkins S.A., Hart C.E., Clowes A.W. Effect of platelet-derived growth factor receptor-alpha and -beta blockade on flow-induced neointimal formation in endothelialized baboon vascular grafts. Circ. Res. 2000, 86:779-786.
10. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., Chesi M., Schinzel A.C., Mckeown M.R., Heffernan T.P., Vakoc C.R., Bergsagel P.L., Ghobrial I.M., Richardson P.G., Young R.A., Hahn W.C., Anderson K.C., Kung A.L., Bradner J.E., Mitsiades C.S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
11. Di Micco R., Fontanals-Cirera B., Low V., Ntziachristos P., Yuen S.K., Lovell C.D., Dolgalev I., Yonekubo Y., Zhang G., Rusinova E., Gerona-Navarro G., Canamero M., Ohlmeyer M., Aifantis I., Zhou M.M., Tsirigos A., Hernando E. Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. Cell Rep. 2014, 9:234-247.
12. Filippakopoulos P., Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 2014, 13:337-356.
13. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., Philpott M., Munro S., Mckeown M.R., Wang Y., Christie A.L., West N., Cameron M.J., Schwartz B., Heightman T.D., La Thangue N., French C.A., Wiest O., Kung A.L., Knapp S., Bradner J.E. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
14. Giese N.A., Marijianowski M.M., Mccook O., Hancock A., Ramakrishnan V., Fretto L.J., Chen C., Kelly A.B., Koziol J.A., Wilcox J.N., Hanson S.R. The role of alpha and beta platelet-derived growth factor receptor in the vascular response to injury in nonhuman primates. Arterioscler. Thromb. Vasc. Biol. 1999, 19:900-909.
15. Gillette T.G., Hill J.A. Readers, writers, and erasers: chromatin as the whiteboard of heart disease. Circ. Res. 2015, 116:1245-1253.
16. Goel S.A., Guo L.W., Liu B., Kent K.C. Mechanisms of post-intervention arterial remodelling. Cardiovasc. Res. 2012, 96:363-371.
17. Goel S.A., Guo L.W., Wang B., Guo S., Roenneburg D., Ananiev G.E., Hoffmann F.M., Kent K.C. High-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferation. PLoS One 2014, 9.
18. Guo L.W., Wang B., Goel S.A., Little C., Takayama T., Shi X.D., Roenneburg D., Direnzo D., Kent K.C. Halofuginone stimulates adaptive remodeling and preserves re-endothelialization in balloon-injured rat carotid arteries. Circ. Cardiovasc. Interv. 2014, 7:594-601.
19. Heldin C.H., Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 1999, 79:1283-1316.
20. Hnisz D., Abraham B.J., Lee T.I., Lau A., Saint-Andre V., Sigova A.A., Hoke H.A., Young R.A. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.
21. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., Michev I., Corvaja N., Briguori C., Gerckens U., Grube E., Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126-2130.
22. Inoue T., Croce K., Morooka T., Sakuma M., Node K., Simon D.I. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc. Interv. 2011, 4:1057-1066.
23. Jechlinger M., Sommer A., Moriggl R., Seither P., Kraut N., Capodiecci P., Donovan M., Cordon-Cardo C., Beug H., Grunert S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Invest. 2006, 116:1561-1570.
24. Jukema J.W., Ahmed T.A., Verschuren J.J., Quax P.H. Restenosis after PCI. Part 2: prevention and therapy. Nat. Rev. Cardiol. 2012, 9:79-90.
25. Kanno T., Kanno Y., Leroy G., Campos E., Sun H.W., Brooks S.R., Vahedi G., Heightman T.D., Garcia B.A., Reinberg D., Siebenlist U., O'shea J.J., Ozato K. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat. Struct. Mol. Biol. 2014, 21:1047-1057.
26. Khan Y.M., Kirkham P., Barnes P.J., Adcock I.M. Brd4 is essential for IL-1beta-induced inflammation in human airway epithelial cells. PLoS One 2014, 9.
27. Li L., Blumenthal D.K., Terry C.M., He Y., Carlson M.L., Cheung A.K. PDGF-induced proliferation in human arterial and venous smooth muscle cells: molecular basis for differential effects of PDGF isoforms. J. Cell. Biochem. 2011, 112:289-298.
28. Loven J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
29. Lu J., Qian Y., Altieri M., Dong H., Wang J., Raina K., Hines J., Winkler J.D., Crew A.P., Coleman K., Crews C.M. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 2015, 22:755-763.
30. Pott S., Lieb J.D. What are Super-Enhancers?. Nat. Genet. 2015, 47:8-12.
31. Shi J., Vakoc C.R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 2014, 54:728-736.
32. Shi X., Chen G., Guo L.W., Si Y., Zhu M., Pilla S., Liu B., Gong S., Kent K.C. Periadventitial application of rapamycin-loaded nanoparticles produces sustained inhibition of vascular restenosis. PLoS One 2014, 9:e89227.
33. Simon D.I. Inflammation and vascular injury. Circ. J. 2012, 76:1811-1818.
34. Wang C.Y., Filippakopoulos P. Beating the odds: BETs in disease. Trends Biochem. Sci. 2015, 40:468-479.
35. Wang B.,.T.T., Zhang M., Shi X., Roenneburg D., Kent K.C., Guo L.-W. Inhibition of epigenetic reader BRD4 mitigates intimal hyperplasia following angioplasty in rat carotid arteries. ATVB Meeting, San Francisco 2015, 194. (April).
36. Wessely R., Schomig A., Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J. Am. Coll. Cardiol. 2006, 47:708-714.
37. Whyte W.A., Orlando D.A., Hnisz D., Abraham B.J., Lin C.Y., Kagey M.H., Rahl P.B., Lee T.I., Young R.A. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
38. Zengerle M., Chan K.H., Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem. Biol. 2015.
39. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., Taylor M.J., Johns C., Chicas A., Mulloy J.C., Kogan S.C., Brown P., Valent P., Bradner J.E., Lowe S.W., Vakoc C.R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.